Cartesian Therapeutics, Inc. (RNAC)
- Previous Close
20.90 - Open
20.98 - Bid 20.86 x 100
- Ask 21.23 x 200
- Day's Range
20.72 - 21.74 - 52 Week Range
11.66 - 42.60 - Volume
123,840 - Avg. Volume
52,580 - Market Cap (intraday)
373.909M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date May 2, 2024 - May 6, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
51.00
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.
www.cartesiantherapeutics.comRecent News: RNAC
Performance Overview: RNAC
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: RNAC
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: RNAC
Valuation Measures
Market Cap
373.91M
Enterprise Value
307.95M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
4.18
Price/Book (mrq)
--
Enterprise Value/Revenue
11.84
Enterprise Value/EBITDA
-1.31
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-22.94%
Return on Equity (ttm)
--
Revenue (ttm)
26M
Net Income Avi to Common (ttm)
-257.26M
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
76.91M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
17.3M